Purpose: Temozolomide, a novel triazene derivative, has shown activity in vitro against lung
cancer as well as against brain metastases from a variety of solid tumors including non …

This study was performed to evaluate the activity of single-agent temozolomide in two
groups of chemotherapy-naı̈ve non-small cell lung cancer (NSCLC) patients, with (12 …

Virtually all patients with advanced non—small-cell lung cancer (NSCLC) relapse.
Docetaxel has an established, Food and Drug Administration—approved role as salvage …

Purpose To determine the efficacy, tolerability, and safety of temozolomide in heavily
pretreated patients with solid tumors and brain metastases. Patients and methods Twenty …

INTRODUCTION:: The primary tumour type most likely to metastasize to the brain is lung
cancer. In heavily pre-treated patients, limited therapeutic option is available and the results …

Background This study was performed to evaluate the tolerability and efficacy of
temozolomide and irinotecan as a second-line regimen in recurrent/metastatic non–small …

Abstract Learning Objectives After completing this course, the reader will be able to: Identify
appropriate treatments for patients with brain metastases from lung cancer with a …

Study Objective. To determine the maximum tolerated dose, dose‐limiting toxicity,
pharmacokinetics, and potential antitumor activity of temozolomide administered as a single …

Abstract BACKGROUND. Temozolomide (TMZ), an oral methylating imidazotetrazinone, has
antitumor activity against gliomas, malignant melanomas, and brain metastasis and is …

Temozolomide, an oral cytotoxic agent with approximately 100% bioavailability after one
administration, has demonstrated schedule-dependent clinical activity against highly …